Novel glutamatergic drugs for the treatment of mood disorders.
about
Neuroplasticity and the next wave of antidepressant strategiesAntidepressants for the treatment of depression in people with cancerInnovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood DisordersEmerging drugs for the treatment of anxietyKetamine exposure in early development impairs specification of the primary germ cell layers.A randomized controlled trial of intranasal ketamine in major depressive disorder.Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects.Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations.Effects of prefrontal cortex and hippocampal NMDA NR1-subunit deletion on complex cognitive and social behaviorsDisturbance of the glutamatergic system in mood disorders.Involvement of adrenoceptors, dopamine receptors and AMPA receptors in antidepressant-like action of 7-O-ethylfangchinoline in mice.Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disordersRepurposing antipsychotics as glioblastoma therapeutics: Potentials and challengesTimosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in miceAlteration by p11 of mGluR5 localization regulates depression-like behaviors.Regulation of persistent sodium currents by glycogen synthase kinase 3 encodes daily rhythms of neuronal excitability.Therapeutic Modulation of Glutamate Receptors in Major Depressive DisorderPregnanolone Glutamate, a Novel Use-Dependent NMDA Receptor Inhibitor, Exerts Antidepressant-Like Properties in Animal Models.The promise of ketamine for treatment-resistant depression: current evidence and future directions.
P2860
Q21129480-9C264ED8-7903-40AB-8AF7-38728CB95AA5Q24187358-79F36C7D-4DDD-4784-85EE-AC240EF18623Q26996411-8E7258E1-F3B2-47C0-A2EC-0155D55D73BAQ27006485-96A500D2-28BE-4E11-8582-E25ADAD92C61Q28083141-AAF543BA-AB1C-40BB-85CF-AAA037CDDEFBQ33715726-4BC8D86C-C3B3-4468-978F-07568498BB4EQ34288196-1672A192-D2F3-4CE1-B449-393A5D99A30CQ34391633-66840B9D-EB0E-4F27-8A24-B422BD479B53Q34466310-5DA96432-0611-42A9-99B3-F2B1901023F4Q35132662-1920F823-39B6-4658-AC33-768DAAD807CDQ35149888-5361E959-BE1E-4D5C-968C-7F67584DD8F2Q36044838-08F0B5B2-41B1-47B5-95DC-FF1335824A3EQ36169850-533B1AD8-8059-42D0-A698-A5717DC044F6Q36524716-21392032-612B-4674-B28D-F9F3C95FBC3DQ36579258-8DB85A69-BE55-4876-BA7E-A282EC19C7FBQ37002871-855D9F12-C9D4-4739-9BBD-568F91B8DA50Q37421658-8FD5FB09-3F39-455B-92BF-9767B63B677BQ37668014-90455A68-0F0F-43C9-AF0A-D3C4E79B555CQ37718994-4AAF4249-4878-454E-ADD6-558C54D800D7Q38343315-04B64428-9BD0-48F6-88F5-04E36B2AB578
P2860
Novel glutamatergic drugs for the treatment of mood disorders.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Novel glutamatergic drugs for the treatment of mood disorders.
@en
type
label
Novel glutamatergic drugs for the treatment of mood disorders.
@en
prefLabel
Novel glutamatergic drugs for the treatment of mood disorders.
@en
P2093
P2860
P356
P1476
Novel glutamatergic drugs for the treatment of mood disorders.
@en
P2093
James W Murrough
Kyle Ab Lapidus
Laili Soleimani
P2860
P304
P356
10.2147/NDT.S36689
P407
P577
2013-08-07T00:00:00Z